| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8603760 | The American Journal of Medicine | 2018 | 31 Pages |
Abstract
In this clinical practice setting, rivaroxaban was associated with lower but statistically nonsignificant rates of post-thrombotic syndrome, which did not appear to be mediated only by an effect on recurrent venous thromboembolism.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Mette PhD, Peter Brønnum PhD, Flemming PhD, Jette Nordstrøm BSc, Craig I. PharmD, Torben Bjerregaard PhD,